China's Diabetes Market Reached US$ 820 Million in 2010

August 11, 2011
Top Quote Driven by an increasing prevalence of diabetes, the total market for Insulin and Non-Insulin Antidiabetics is expected to reach sales worth US$ 2803 Million by 2015. End Quote
  • (1888PressRelease) August 11, 2011 - As the second largest economy of the world, China enjoys pink of health but its affluence is giving rise to another sickness- a rapid increase in a life-style disease called diabetes. With the Chinese Population getting richer, fatter and less mobile, there has been a surge in the prevalence of diabetes. Further fuelled by rising disposable incomes, the diabetes market- Non-Insulin Anti-diabetics and Insulin, is expanding by more than 25% percent a year, and thus creating lucrative opportunities for global pharmaceutical companies at a time when rates in the more developed markets have declined.

    China's diabetes market grew at CAGR of 27% in the last five years with sales touching US$ 820 Million in 2010. In a country with around 10% of the total population being above 65 years of age, nearly 100 Million people obese and overweight, and with urbanization rates in an increasing mode, we expect the market to more than quadruple vis-à-vis its present level by 2015.

    IMARC's new report "China Diabetes Market Outlook (2010-2015)" gives a deep insight into the Chinese diabetes market. The research study serves as an analytical as well as statistical tool to understand the epidemiology, trends, market structure and segmentation, competitive landscape, drivers, restraints and the outlook of the diabetes market in China. The report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are looking to foray into the Chinese diabetes market in some form or the other.

    Table of Contents:

    1. Executive Summary
    2. Diabetes Disease Overview
    2.1 WHAT IS DIABETES?
    2.2 DIABETES DIAGNOSIS AND TREATMENT
    2.2.1 Diagnosis
    2.2.2 Treatment
    2.3 DIABETES COMPLICATIONS
    3. The Chinese Diabetes Market: Why is it so Lucrative?
    3.1 CHINA HAS ONE OF THE LARGEST DIABETES PATIENT POOLS IN THE WORLD.
    3.2 CHINA REPRESENTS ONE OF THE FASTEST GROWING MARKETS GLOBALLY
    3.3 INCREASING AFFORDABILITY OF HEALTHCARE
    3.4 MORE THAN A BILLION DOLLARS WORTH OF MARKET REMAINS UNTAPPED
    3.5 A BETTER IPR REGIME IS DRIVING THE LAUNCH NEW AND INNOVATIVE DRUGS
    4. Drivers of Diabetes in China
    4.1 AGEING POPULATION
    4.2 INCREASING OBESITY LEVELS
    4.3 URBANIZATION
    5. The Chinese Diabetes Epidemiology
    5.1 TOTAL PREVALENCE
    5.1.1 Urban and Rural Prevalence
    5.1.2 Prevalence of Diabetes by Sex
    5.1.3 Prevalence of Diabetes by Age Group
    5.2 DIAGNOSIS AND TREATMENT RATES IN CHINA
    6. The Chinese Diabetes Market
    6.1 MARKET TREND (2005-2009)
    6.2 MARKET SEGMENTATION (2005-2009)
    6.3 MARKET FORECASTS (2010-2015)
    7. The Chinese Non-Insulin Anti-diabetics Market
    7.1 MARKET TREND (2005-2009)
    7.2 COMPETITIVE LANDSCAPE (2005-2009)
    7.3 MARKET FORECASTS (2010-2015)
    7.4 MARKET SEGMENTATION (2005-2015)
    7.4.1 Alpha-Glycosidase Inhibitors
    7.4.1.1 Market Trend (2005-2009)
    7.4.1.2 Competitive Landscape
    7.4.1.2.1 Share of Key Players
    7.4.1.2.2 Portfolio of Key Players
    7.4.1.3 Market Forecasts (2010-2015)
    7.4.2 Glinides
    7.4.2.1 Market Trend (2005-2009)
    7.4.2.2 Competitive Landscape
    7.4.2.2.1 Share of Key Players
    7.4.2.2.2 Portfolio of Key Players
    7.4.2.3 Market Forecasts (2010-2015)
    7.4.3 Glitazones
    7.4.3.1 Market Trend (2005-2009)
    7.4.3.2 Competitive Landscape
    7.4.3.2.1 Share of Key Players
    7.4.3.2.2 Portfolio of Key Players
    7.4.3.3 Market Forecasts (2010-2015)
    7.4.4 Sulphonylurea
    7.4.4.1 Market Trend (2005-2009)
    7.4.4.2 Competitive Landscape
    7.4.4.2.1 Share of Key Players
    7.4.4.2.2 Portfolio of Key Players
    7.4.4.3 Market Forecasts (2010-2015)
    7.4.5 Biguanides
    7.4.5.1 Market Trend (2005-2009)
    7.4.5.2 Competitive Landscape
    7.4.5.2.1 Share of Key Players
    7.4.5.2.2 Portfolio of Key Players
    7.4.5.3 Market Forecasts (2010-2015)
    7.4.6 Dpp-IV Inhibitors
    7.4.6.1 Competitive Landscape
    7.4.6.1.1 Share Forecast for Key Players
    7.4.6.1.2 Portfolio of Key Players
    7.4.6.2 Market Forecasts (2010-2015)
    7.4.7 Glp-1 Agonists
    7.4.7.1 Competitive Landscape
    7.4.7.1.1 Share Forecast for Key Players
    7.4.7.1.2 Portfolio of Key Players
    7.4.7.2 Market Forecasts (2010-2015)
    7.4.8 All other Classes
    7.4.8.1 Market Trend (2005-2009)
    7.4.8.2 Competitive Landscape
    7.4.8.2.1 Share of Key Players
    7.4.8.2.2 Portfolio of Key Players
    7.4.8.3 Market Forecasts (2010-2015)
    8. The Chinese Insulin Market
    8.1 MARKET TREND (2005-2009)
    8.2 MARKET SEGMENTATION BY MOLECULE (2005-2009)
    8.3 MARKET SEGMENTATION BY MODE OF ACTION
    8.4 COMPETITIVE LANDSCAPE
    8.4.1 Share of key Players
    8.4.2 Insulin Portfolio of Key Players
    8.5 MARKET FORECASTS (2005-2010)
    9. Road Blocks
    9.1 MILLIONS DON'T EVEN KNOW IF THEY HAVE DIABETES
    9.2 DESPITE THE LARGE POPULATION BASE, AVERAGE SPENDING ON DIABETES REMAINS FAIRLY LOW
    9.3 REGULATORY & BUREAUCRATIC HURDLES
    9.4 LARGE FINANCIAL DISPARITY

    To buy the complete report or to get a free sample:
    Call: +91-120-425-6531 (Asia), +44-844-774-9660 (Europe), +1-631-791-1145 (America)
    Email: sales ( @ ) imarcgroup dot com

    For more information please visit: http://www.imarcgroup.com/china-diabetes-market-report-and-outlook-2010-2015/

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information
  • Krishna Sharma
  • Imarc Group
  • 21/601 Eastend Apartment Mayur Vihar Phase-1 Extention Delhi-110096, India
  • 110096
  • Voice: 91-11-43095788
  • Visit our Site
Over Satisfied Users & Approved Press Releases
© Copyright 2005-2024, 1888 Press Release. All Rights Reserved